Effects of PCSK9 Inhibition on Coronary Atherosclerosis Regression of Nontarget Lesions after Primary Percutaneous Coronary Intervention in Acute Coronary Syndrome Patients

AIMS: To evaluate the regression of coronary atherosclerosis with proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition in acute coronary syndrome (ACS) patients following primary percutaneous coronary intervention (PPCI). Methods and Result. We examined 40 nontarget lesions in 17 ACS pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yongjun, Yang, Mingming, Chen, Xi, Zhang, Rui, Li, Jing, Zhang, Xiaoguo, Zuo, Pengfei, Ma, Genshan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9807301/
https://www.ncbi.nlm.nih.gov/pubmed/36632288
http://dx.doi.org/10.1155/2022/4797529

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9807301/
https://www.ncbi.nlm.nih.gov/pubmed/36632288
http://dx.doi.org/10.1155/2022/4797529

Ejemplares similares